CIMT 2015: The right patient for the right therapy - Report on the 13th annual meeting of the Association for Cancer Immunotherapy

Kranz, Lena M.; Birtel, Matthias; Krienke, Christina; Grunwitz, Christian; Petschenka, Jutta; Reuter, Kerstin C.; Roemer, Niels van de; Vascotto, Fulvia; Vormehr, Mathias; Kreiter, Sebastian; Diken, Mustafa

doi:10.1080/21645515.2015.1068485

Cited by 1 publication

(1 citation statement)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Taken apart, it can be concluded that DC therapy and PD-1 blocking approaches will prove best in a combinatorial setting subject to the malignancy and the disease status ( 157 ). In this perspective, the search for biomarkers predicting response to DC therapy and to PD-1 pathway blockade is imperative ( 20 , 155 , 158 ).…”

Section: Future Perspectivesmentioning

confidence: 99%

Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer

et al. 2018

View full text Add to dashboard Cite

Two decades of clinical cancer research with dendritic cell (DC)-based vaccination have proved that this type of personalized medicine is safe and has the capacity to improve survival, but monotherapy is unlikely to cure the cancer. Designed to empower the patient’s antitumor immunity, huge research efforts are set to improve the efficacy of next-generation DC vaccines and to find synergistic combinations with existing cancer therapies. Immune checkpoint approaches, aiming to breach immune suppression and evasion to reinforce antitumor immunity, have been a revelation in the immunotherapy field. Early success of therapeutic antibodies blocking the programmed death-1 (PD-1) pathway has sparked the development of novel inhibitors and combination therapies. Hence, merging immunoregulatory tumor-specific DC strategies with PD-1-targeted approaches is a promising path to explore. In this review, we focus on the role of PD-1-signaling in DC-mediated antitumor immunity. In the quest of exploiting the full potential of DC therapy, different strategies to leverage DC immunopotency by impeding PD-1-mediated immune regulation are discussed, including the most advanced research on targeted therapeutic antibodies, lessons learned from chemotherapy-induced immune activation, and more recent developments with soluble molecules and gene-silencing techniques. An overview of DC/PD-1 immunotherapy combinations that are currently under preclinical and clinical investigation substantiates the clinical potential of such combination strategies.

show abstract